---
title: "HENLIUS's two products have been approved by the European Commission for the treatment of osteoporosis in specific populations and other indications"
description: "HENLIUS announced that its products BILDYOS and BILPREVDA have been approved by the European Commission for the treatment of osteoporosis in specific populations. This approval covers all EU member st"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/258059688.md"
published_at: "2025-09-19T09:57:45.000Z"
---

# HENLIUS's two products have been approved by the European Commission for the treatment of osteoporosis in specific populations and other indications

> HENLIUS announced that its products BILDYOS and BILPREVDA have been approved by the European Commission for the treatment of osteoporosis in specific populations. This approval covers all EU member states as well as Iceland, Liechtenstein, and Norway, with indications including osteoporosis in high-risk postmenopausal women and men, bone loss in men with prostate cancer, and prevention of bone-related events in adults with advanced bone malignancies

HENLIUS (02696.HK) announced that the marketing authorization applications (MAAs) for its products BILDYOS and BILPREVDA have been approved by the European Commission. The trademarks for these products are registered by N.V. Organon in the EU. This approval means that the two products have received centralized marketing authorization in all EU member states as well as Iceland, Liechtenstein, and Norway.

The approved indications are for all indications for Prolia and XGEVA marketed in the EU, specifically:

The indication for BILDYOS is the treatment of osteoporosis in postmenopausal women and men at high risk of fractures; treatment of bone loss associated with hormone ablation in men with high-risk prostate cancer; and treatment of bone loss related to long-term systemic glucocorticoid therapy in adult patients at high risk of fractures.

The indications for BILPREVDA include the prevention of skeletal-related events in adults with advanced bone malignancies; and treatment of patients with giant cell tumors of the bone that are not amenable to surgical resection or may lead to severe functional impairment after surgical resection, including adults and skeletally mature adolescents

### Related Stocks

- [02696.HK - HENLIUS](https://longbridge.com/en/quote/02696.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美國食品藥品監督管理局（FDA）已接受復宏漢霖漢貝泰貝伐珠單抗注射液的生物製品許可申請 | 上海復宏漢霖生物科技有限公司宣佈，FDA 已接受其 HANBEITAI（貝伐單抗注射液）的生物製品許可申請。該申請包括多種適應症，如轉移性結直腸癌以及各種類型的肺癌和卵巢癌。該提交基於數據顯示與參考藥物高度相似且沒有臨牀上顯著差異。此消息僅 | [Link](https://longbridge.com/en/news/272384057.md) |
| 上海復宏漢霖生物技術公司獲得中國證監會批准其 H 股全流通 | 上海復宏漢霖生物科技股份有限公司已獲得中國證券監督管理委員會（CSRC）批准，全面流通 182,645,856 股未上市股份。這使得這些股份可以轉換並在香港證券交易所上市。轉換必須在 12 個月內完成，否則將需要提交更新的備案 | [Link](https://longbridge.com/en/news/272805634.md) |
| 報告指出，性別薪酬差距需要 30 年才能縮小 | 根據工會大會（TUC）的一份報告，性別薪酬差距預計需要 30 年才能縮小，目前女性的收入比男性低 12.8%，相當於每年少賺 2,548 英鎊。造成這一差距的因素包括由於照顧責任而從事兼職工作。報告強調了各行業之間的顯著差異，特別是對年長女 | [Link](https://longbridge.com/en/news/275988803.md) |
| 隨着要求公開愛潑斯坦文件的壓力增大，FBI 員工收集了針對其他男性的指控 | 隨着對釋放愛潑斯坦文件的壓力加大，FBI 員工彙編了與傑弗裏·愛潑斯坦有關的男性的指控，包括唐納德·特朗普和比爾·克林頓等知名人物。一份 21 頁的演示文稿概述了各種聯邦調查，並列出了與愛潑斯坦相關的姓名，其中一些指控尚未得到證實。由於未能 | [Link](https://longbridge.com/en/news/275395734.md) |
| 香港警方逮捕 2 人，涉及入境航班上價值 30 萬港元的手錶盜竊案 | 香港警方逮捕了兩名嫌疑人，他們在從阿布扎比入境的航班上從一名乘客的揹包中盜走了一隻價值 30 萬港元的手錶。這起盜竊事件是由一名男性乘客報告的，他發現自己的手錶從頭頂行李艙中不翼而飛。嫌疑人是一名 40 歲的本地女性和一名 32 歲的來自中 | [Link](https://longbridge.com/en/news/275853880.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.